ALFA Finder| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 28.2 | 28.0 | 26.6 |
| Other income | -0.1 | 0.2 | 0.6 |
| Total income | 28.1 | 28.1 | 27.3 |
| Profit before exceptional items & tax | 1.2 | 1.2 | 1.1 |
| Profit before tax | 1.2 | 1.2 | 1.1 |
| Net profit | 1.0 | 1.1 | 1.0 |
| Operating margin | 4.3% | 4.3% | 4.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +0.00% |
|---|---|
| Net profit, quarter on quarter | -9.10% |
| Revenue, year on year | +6.00% |
| Operating profit, year on year | +160.00% |
| Operating profit, quarter on quarter | +30.00% |
BSE results filing, NSE: GODAVARI. Figures extracted from the filing.
Godavari Drugs Ltd: key numbers
- Share price
- ₹118.10
- Market cap
- ₹119.6 Cr
- Revenue (annual)
- ₹105.8 Cr
- Net profit (annual)
- ₹4.09 Cr
- P/E (TTM)
- 29.1×Sector 43.8×
- Promoter holding
- 44.54%+4.31% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Godavari Drugs Ltd
All →Godavari Drugs Board Meeting Date
Godavari Drugs will hold a board meeting on 11 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. The trading window stays closed until 48 hours after the results are declared.
Godavari Drugs Convertible Warrants
Godavari Drugs allotted 7,86,690 equity shares to promoter-category allottees on conversion of warrants. The balance consideration of Rs 5.25 Crore was received at an issue price of Rs 89.
- Value
- ₹5.25 Cr
Godavari Drugs Other Announcement
Godavari Drugs filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing is a routine Regulation 31 disclosure with no transaction.
Godavari Drugs Other Announcement
Godavari Drugs Limited changed its Corporate Identification Number (CIN) following an alteration to its Memorandum of Association's Object Clause. The Ministry of Corporate Affairs registered the change on October 16, 2026.
Godavari Drugs Debt & Borrowing: ₹34 Cr
Godavari Drugs Limited's board approved availing working capital limits of Rs. 34 Crore from ICICI Bank. The facility is within existing shareholder-approved borrowing limits.
- Value
- ₹34.00 Cr
Godavari Drugs Annual General Meeting
Godavari Drugs held its 38th Annual General Meeting on September 25, 2026, via video conferencing. Shareholders approved financial statements, director re-appointment, and object clause alteration.